Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab

Satoshi Otsu ； Yoshinori Hirashima ； Kazuo Nishikawa ； Hiroyuki Sakashita ； Ryotaro Morinaga ； Koichiro Watanabe ； Kuniaki Shirao

《Japanese Clinical Medicine》 2014 (2014/12) Pp. 19-23

https://doi.org/10.4137/JCM.S15553

並列摘要

This study was conducted to investigate the toxicity and efficacy of modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer with particular regard to oxaliplatin-induced neuropathy. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (version 3.0). The evaluation was especially focused on grade 2 oxaliplatin-induced neuropathy. The estimated median treatment time to occurrence of grade 2 sensory neuropathy was 7.3 months. The estimated median cumulative dose to occurrence of grade 2 sensory neuropathy was 931 mg/m^2. This study clarified the treatment time from first dose as well as the cumulative dose of oxaliplatin leading to grade 2 neuropathy. It may be important to institute some clinical countermeasures when grade 2 neuropathy occurs so as to reduce the chance of progression to irreversible grade 3 neuropathy.

並列關鍵字

oxaliplatin ； neuropathy ； colorectal cancer ； modified FOLFOX6